Arsenal Capital Partners Expands Team with Joshua Schultz
Arsenal Capital Partners, a preeminent private equity firm focused on fostering technology-driven market leaders in the healthcare and industrial sectors, has announced the addition of Joshua Schultz to its dynamic healthcare team as an Operating Partner.
Expertise in Pharma Services and Medical Technology
In his new role, Joshua Schultz will leverage his substantial expertise to drive investments in pharmaceutical services and medical technology. His impressive background includes a recent tenure as the CEO of Cytel, where he significantly expanded the company’s capabilities in advanced analytics within the life sciences sector. During his five years of stewardship, he transitioned Cytel from a recognized statistical software and consulting entity into a comprehensive analytics powerhouse. This transformation benefitted over 500 clients, including the world’s premier pharmaceutical companies.
Leadership at Cytel and PAREXEL
Before joining Cytel, Schultz made significant contributions to PAREXEL International. Serving there for over 13 years, he held the role of Senior Vice President, where he consolidated several operational areas including market access and pharmacovigilance. His education credentials include dual Bachelor’s degrees from the University of Pennsylvania and a Master of Philosophy from Cambridge University, solidifying his rich knowledge base in economics and business.
Commitment to Innovation in Healthcare
Gene Gorbach, an Investment Partner at Arsenal, praised Schultz’s leadership skills and his proven ability to cultivate and transform pharmaceutical services companies. Gorbach emphasized that Schultz’s deep industry insights will be invaluable as Arsenal seeks to enhance its investment strategies and build health-focused companies that lead the market.
Vision for Future Healthcare Solutions
Expressing his enthusiasm, Joshua Schultz stated, "Innovation offers us the ability to build technology-rich and market-leading companies across the healthcare continuum. Advances in data analytics are transforming healthcare, enabling more personalized, predictive, and preventative care. I'm honored to join Arsenal in its mission to improve health outcomes and revolutionize the healthcare system." This strategic move highlights Arsenal’s ongoing commitment to advancing healthcare innovation.
About Arsenal Capital Partners
Arsenal Capital Partners has been a trailblazer in private equity investments dedicated to creating growth in the industrial and healthcare sectors since its establishment in 2000. The firm has successfully amassed over $10 billion in institutional equity funds, executing more than 300 acquisitions. With a focus on partnering with visionary management teams, Arsenal specializes in nurturing companies that are not only leaders in their respective markets but are also poised for exceptional growth.
Frequently Asked Questions
What is Arsenal Capital Partners' new strategy with Joshua Schultz?
Arsenal Capital Partners aims to leverage Joshua Schultz's expertise in pharmaceutical services and medical technology to enhance its investment strategies and improve healthcare outcomes.
What prior experience does Joshua Schultz bring?
Joshua Schultz has a wealth of experience as the former CEO of Cytel and Senior VP at PAREXEL, where he oversaw critical areas such as market access and analytics.
How does Arsenal Capital Partners support healthcare companies?
Arsenal aids healthcare companies by providing strategic investments and operational support aimed at fostering growth and technological advancement.
When was Arsenal Capital Partners established?
Arsenal Capital Partners was founded in 2000 and has since built a significant portfolio within the industrial and healthcare sectors.
What notable companies has Arsenal Capital Partners acquired?
Arsenal has completed over 300 platform and add-on acquisitions, driving substantial growth in its market-leading companies.
